国际放射医学核医学杂志
國際放射醫學覈醫學雜誌
국제방사의학핵의학잡지
INTERNATIONAL JOURNAL OF RADIATION MEDICINE AND NUCLEAR MEDICINE
2010年
5期
299-301
,共3页
格雷夫斯病%碘放射性同位素%近距离放射疗法%青少年
格雷伕斯病%碘放射性同位素%近距離放射療法%青少年
격뢰부사병%전방사성동위소%근거리방사요법%청소년
Graves disease%Iodine radioisotopes%Brachytherapy%Adolescent
目的 研究131I治疗青少年Graves病的可行性和安全性.方法 回顾性分析58例经131I治疗的青少年Graves病患者,分别于131I(剂量:148～240.5MBq)治疗前和治疗6个月后,用化学发光免疫法检测血清游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)水平及用彩色多普勒超声测量甲状腺大小;随访2～7年,评价疗效.结果 治疗6个月后,血清FT3和FT4水平明显降低(t=12.43,t=21.21,P均＜0.01),TSH水平明显升高(t=10.34,P＜0.01),甲状腺体积明显缩小.58例患者中,治愈31例(53.45%),好转16例(27.59%),无效7例(12.07%),甲减3例(5.17%),复发1例(1.72%).结论 131I治疗青少年Graves病安全有效.
目的 研究131I治療青少年Graves病的可行性和安全性.方法 迴顧性分析58例經131I治療的青少年Graves病患者,分彆于131I(劑量:148～240.5MBq)治療前和治療6箇月後,用化學髮光免疫法檢測血清遊離三碘甲腺原氨痠(FT3)、遊離甲狀腺素(FT4)、促甲狀腺激素(TSH)水平及用綵色多普勒超聲測量甲狀腺大小;隨訪2～7年,評價療效.結果 治療6箇月後,血清FT3和FT4水平明顯降低(t=12.43,t=21.21,P均＜0.01),TSH水平明顯升高(t=10.34,P＜0.01),甲狀腺體積明顯縮小.58例患者中,治愈31例(53.45%),好轉16例(27.59%),無效7例(12.07%),甲減3例(5.17%),複髮1例(1.72%).結論 131I治療青少年Graves病安全有效.
목적 연구131I치료청소년Graves병적가행성화안전성.방법 회고성분석58례경131I치료적청소년Graves병환자,분별우131I(제량:148～240.5MBq)치료전화치료6개월후,용화학발광면역법검측혈청유리삼전갑선원안산(FT3)、유리갑상선소(FT4)、촉갑상선격소(TSH)수평급용채색다보륵초성측량갑상선대소;수방2～7년,평개료효.결과 치료6개월후,혈청FT3화FT4수평명현강저(t=12.43,t=21.21,P균＜0.01),TSH수평명현승고(t=10.34,P＜0.01),갑상선체적명현축소.58례환자중,치유31례(53.45%),호전16례(27.59%),무효7례(12.07%),갑감3례(5.17%),복발1례(1.72%).결론 131I치료청소년Graves병안전유효.
Objective To study the feasibility and curative effect of 131I therapy for youngsters with Graves' disease. Methods Retrospective analyzed 58 youngsters with Graves' disease, to compare the serum free triiodthyroine (FT3), free thyroxine (FT4) and thyroid-stimulating hormone(TSH ) levels with chemiluminescent immunoassay and to measure the thyroid gland size with color Doppler diagnostic apparatus before and after six months of 131I (148-240.5 MBq) therapy, then followed up for 2-7 years, and clinical efficacy was evaluated according to the results. Results After 6 months of therapy, the levels of FT3 and FT4 were significantly decreased(t=12.43, t=21.21, P＜0.01), the level of TSH was significantly increased (t=10.34, P＜0.01 ), and thyroid volume was decreased obviously. Of the 58 patients, 31 (53.45%)patients were cured, 16 (27.59%) were much better than before, and 7 (12.1%) were invalid, 3 (5.17%) were temporary hypothyroid, 1 (1.72%) recrudesced. Conclusion 131I is an effective therapy which is safe and economical to youngsters with Graves' disease.
